Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTERACT5
NCT06763055Phase 3Recruiting
- Sponsor
- The George Institute for Global Health
- Start
- Feb 2025
- Primary completion
- Jan 2028
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 2
01
Overview
Phase 3, randomised, single-blind trial of deferoxamine and colchicine in intracerebral hemorrhage (ICH) (4 arms), sponsored by The George Institute for Global Health. Primary endpoint: modified Rankin Scale scores at 6 months. Started Feb 2025; status: recruiting.
02
Drugs
deferoxaminecolchicine
03
Conditions
intracerebral hemorrhage (ICH)
Beyond the preview
Go deeper on NCT06763055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06763055.